DOCSLIB.ORG

( 12 ) Patent Application Publication (10 ) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
( 12 ) Patent Application Publication (10 ) Pub INDUS 20190328899A1 IN (19 ) United States ( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2019/0328899 A1 Hechler et al. (43 ) Pub . Date : Oct. 31 , 2019 (54 ) AMANITIN ANTIBODY CONJUGATES Publication Classification (51 ) Int. Ci. ( 71) Applicant : Heidelberg Pharma Research GmbH , A61K 47/68 (2006.01 ) Ladenburg (DE ) A61P 35/00 (2006.01 ) CO7K 14/37 (2006.01 ) ( 72 ) Inventors: Torsten Hechler, Lautertal (DE ) ; COOK 16/28 (2006.01 ) Michael Kulke , Ludwigshafen am (52 ) U.S. CI. Rhein (DE ) ; Christian Lutz , Weinheim CPC A61K 47/6831 ( 2017.08 ) ; A61K 47/6867 (DE ) ; Andreas Pahl, Heidelberg (DE ) ; ( 2017.08 ) ; CO7K 16/2878 ( 2013.01 ) ; A61P Christoph Müller , Birkenau (DE ) ; 35/00 ( 2018.01 ) ; CO7K 14/37 (2013.01 ) ; A61K Werner Simon , Hüffelsheim (DE ) ; Anikó Pálfi , Hirschberg a.d. Bergstra (3e 47/6889 ( 2017.08 ) (DE ) (57 ) ABSTRACT (21 ) Appl . No.: The invention relates to a conjugate comprising ( a ) an 16 /470,950 amatoxin comprising ( i) an amino acid 4 with a 6 '- deoxy (22 ) PCT Filed : Dec. 22 , 2017 position ; and ( ii ) an amino acid 8 with an S -deoxy position ; ( b ) a BCMA- binding moiety comprising ( i) the variable ( 86 ) PCT No.: PCT /EP2017 / 084431 domains ofhumanized antibody J22.9 - ISY , and ( ii ) a heavy chain constant region comprising a D265C mutation ; and ( c ) $ 371 ( c ) ( 1 ) , a protease - cleavable linker linking said amatoxin and said ( 2 ) Date : Jun . 18 , 2019 target -binding moiety . The invention furthermore relates to a pharmaceutical composition comprising such conjugate , (30 ) Foreign Application Priority Data particularly for use in the treatment of multiple myeloma. Dec. 23 , 2016 ( EP ) 16206849.8 Specification includes a Sequence Listing . R SCH?1 H?CBTR HN - CH - CO 3CH -CO -A - CH -co -wc 5 ' - co 4 CO 3 ' PRANH CH , CH 2 7 ' HC HO 6 -CH3 CH2 ?? 0 CO - CH -NH OL H A CO - CH RY 8 7 R1 R2 R3 R4 a - amanitin OH OH NH2 OH B - amanitin OH OH OH OH Y - amanitin H OH NH2 OH E - amanitin H OH OH OHOH amanin OH OH OH H amaninamide OH OH NH2 I amanullin H H NH2 OH amanullinic acid H H ?? OH Y -amanin H OH OH H Y - amaninamide I OH NH2 I Patent Application Publication Oct. 31 ,2 2019 Sheet 1 of 32 US 2019/0328899 A1 FIGURE 1 R — 1 CH2 ?.?. ? Y R , 4 ? 5 HN - CH - CO - N - CH - CO - N CHz CO 3 H 4 * 5 6 ' NH 3 " R , CHE ?? 2 HC ?? (? 2 N 6 -N CH , 1 ?? , ?? : CO - CH - N - CO - CH - NH ZI 8 H 7 R , ?Y. B R1 R , R3 R , a - amanitin ?? ?? NH2 ?? B - amanitin ?? ?? ?? ?? y - amanitin ? ?? NH2 ?? E - amanitin ? ?? ?? ?? amanin ?? ?? ?? ?. amaninamide ?? ?? NH2 ? amanullin ? ? NH2 ?? amanullinic acid ? ? ?? ?? y - amanin ? ?? ?? ?. y -amaninamide H ?? NH2 H Patent Application Publication Oct. 31 ,2 2019 Sheet 2 of 32 US 2019/0328899 Al FIGURE 2 PBS, pH 7.4 PBS , pH 7.4 + cysteine heavy chain light chain day 0 day 5 day 0 day 5 Patent Application Publication Oct. 31 , 2019 Sheet 3 of 32 US 2019/0328899 A1 17,0 16,8 CH3 CH2-CH3 16,6 NH HC- CO -NH ym 16,216,4 HO CH2 -NH-CH2 -CO Apment ............ CO NH -NH 15,215,415,615,816,0 Amanitin+Cyst=6dalpha- CH2 - -CH-NH ?.?. O=5 wynamagrantumengumumnyamenganggapngmgatunog DAD-CH1305nm -NH-COCH -CH2OH CO 15,0 -CH 14,8 CH CH2 HN-CH OC-----CH NH2 Amanitin48h+Cyst=alpha- ?3?. CH Minutes DAD-CH1305nm H OH 13111111111 Amanitin+Cyst=24halpha- 12,412,612,813,013,213,413,613,814,014,214,414,6 DAD-CH1305nm mummymwanyamawangumwenyemamynaperymenmampumenemaninyamengenangage alpha-Amanitin+Cyst=0 DAD-CH1305nm 12,012,2 FIGURE3 0 1600 1500 1400 1300 1200 1100 1000 900 800 700 600 500 400 300 200 100 -100 MAU Patent Application Publication Oct. 31 , 2019 Sheet 4 of 32 US 2019/0328899 Al CH2-CH3 CH3 16,216,416,616,817,0 NH HCHC CO NH" OH -CO-CH2 -CO-NHCH2 16,0 NH -NH CH2 15,215,415,615,8 -NH-CH H2C -CH beta-Amanitin+Cyst=6d CO DAD-CH1305nm CH2OH CO NH HO CH CH CH CH CH2 OH H?C. HN CH beta-Amanitin+Cyst=48h Minutes DAD-CH1305nm HO beta-Amanitin+Cyst=24h 12,012,212,412,612,813,013,213,413,613,814,014,214,414,614,815,0 DAD-CH1305nm betaAmanitin-+Cyst=0 DAD-CH1305nm FIGURE4 0 1200 1100 1000 900 800 700 600 500 400 300 200 100 -100 MAU Patent Application Publication Oct. 31 , 2019 Sheet 5 of 32 US 2019/0328899 A1 17,0 171TTTTTTTT 16,616,8 ?????????'?????????????? -?????"??"??????????????????? ?????????????????? 14,014,214,414,614,815,015,215,415,615,816,016,216,4 Amanin+Cyst=6d ATTTTTTTTTT DAD-CH1305nm CH2-CHE CH3 ??????????? F Minutes Cys48ht=Amanin+ DAD-CH1305nm -CH----NH---CO-CH2 -NH-CH--CONHCH2 youCH? H2C Cys=24h+tAmanin PITTTTTTTTTTT 12,612,813,013,213,413,613,8 DAD-CH1305nm ??.?? TTTTT CH ennen COOHH2C- CH ??????????'? H?O, Cyst=0Amanin+ DAD-CH1305nm HO ?????????- 12,012,212,4 FIGURE5 0 375 350 325 300 275 250 225 200 175 150 125 100 75 50 25 -25 MAU Patent Application Publication Oct. 31 , 2019 Sheet 6 of 32 US 2019/0328899 A1 16,817,0 HDP30.2105+Cyst=6d 14,014,214,414,614,815,015,215,415,615,816,016,216,416,6 DAD-CH1305nm CH3 CH2-CH3 CO HC- HDP30.2105+Cyst=48h Minutes DAD-CH1305nm CH-NHCO---CH2 -NH-CHCONHCH2 NH H2C CH? HDP30.2105+Cyst=24h 201 DAD-CH1305nm --CH2OH OH CH -CH--NH-CO 12,012,212,412,612,813,013,213,413,613,8 CH CH COOHH2C-- HDP30.2105+Cyst=0 H?C. DAD-CH1305nm De FIGURE6 40 20 260 240 220 200 180 160 140 120 100 80 60 -20 MAU Patent Application Publication Oct. 31 , 2019 Sheet 7 of 32 US 2019/0328899 Al beta-Amanitin SOIZ*0€do Amanitinsentenelinowealpha- ujuewyuitwerking* ??? .**odawcyklus FIGURE7 iSWAMP Patent Application Publication Oct. 31 , 2019 Sheet 8 of 32 US 2019/0328899 Al HDP30.2115 N HN NH HN 'NH H 0 HN HDP30.1699 HN OH HO H HO PHN NH HO abzslysOberlig HO 30.2060HDP NH HN N. HO NH NH OH ?? FIGURE8 HO Patent Application Publication Oct. 31 , 2019 Sheet 9 of 32 US 2019/0328899 Al 567891234 T-D265C30.2115(n.d.)do T-D265C30.2115(n.d.)d4 T-D265C30.2115(n.d.)d10 T-D265C30.1699(2.8)do T-D265C30.1699[2.8)-d4 T-D265C30.1699[2.8)-010 T-D265C30.2060(2.3)do T-D265C30.2060(2-3)-d10 ADCsincubatedinMousePlasma T-D265C30.2060[2.31-04 5 7 2 FIGURE9 250 130 95. 55 36. 28 17. 123456789 123456789 ADCsincubatedinHumanPlasma ADCsincubatedinPBS SIA 250 130 95 7255 36. 17 250 130 95 55 36 17 Patent Application Publication Oct. 31 , 2019 Sheet 10 of 32 US 2019/0328899 A1 T-D265C30.2115CLd4 4.049e-011 Concentration(M) 10-1410-1310-1210-1110-1010-910-710-8 T-D265C30.2115CLinHumanplasma T-D265C30.2115OLdo 0+TTTTTTTTTTTTTTTTTTTTTTTTATTTT 2.013e-011 EC50 120 110 100 90 80 70 60 50 40 30 20 10 ] % [ Viability 107 10-8 T-0265C30.206004 2.715e-010 Concentration[M] T-D266C30,206004 T-D2650-30,2060-00 T-D265C30.206000 T-D265C30.2060inHumanplasma 10-1410-1310-1210-1110:10109 3.856e-011 EC50 1207 110 100 90 80 70 60 50 40 30 20 10 0 afterincubationinHumanplasmaCytotoxicityonSKBR-3cells ] % [ Viability T-D2650-30.169904 3.022e-010 Concentration[M] 10710-1410-1310-1210:1110-1010-910-8 T-D265C30.1699-04 T-D265C30.1699inHumanplasma T-D2650-30.1699do 2.3589-011 FIGURE10 0+TTTTTTTTTTTTT EC50 120 110 100 90 80 70 60 50 40 30 20 10 ] % [ Viability Patent Application Publication Oct. 31 , 2019 Sheet 11 of 32 US 2019/0328899 Al 10-7 T-D2650-30.2115CL04 3.091e-011 Concentration[M] T-D2650-30.2115CL04 T-D265C30.2115CLinMouseplasma 10-1410-1310-1210-1110-1010-910-8 T-D2650-30.2115CLdo 2.130e-011 C50 120my 110 100 90 80 70 60 50 40 30 20 10 0TTTTTTTTTTTTTTTTTTTTT ] % [ Viability 10-7 10-8 TITLE T-0265C30.2060-04 1.285e-010 10-9 Concentration[M] T-D266C30.200004 T-D265C30.2060do T-D265C30.2060inMouseplasma 2.954e-011 10-1410-1310-1210-1110-10 EC50 110 904 .80 70 60 50 40 304 20 10 0TTTTTTTTTTT 1207 100 plasmaSKBR-3cellsafterincubationinMouseCytotoxicityon ] % [ Viability T-D265C30.169904 4.8660-010 Concentration[M] T-D265C30.1699.d4 10-810-1410-1310-1210-1110-1010-910-7 T-D265C30.1699do T-D265C30.1699inMouseplasma 1.887e-011 FIGURE11 TTTTTTTTTTOtto EC50 120 110 1007 90 80 70 60 50 40 30 204 10 ] % [ Viability Patent Application Publication Oct. 31 , 2019 Sheet 12 of 32 US 2019/0328899 Al 10-7 10-8 T-D265C30.2115CLd4 4.7292-011 Concentration[M] T-D265C30.2115CLdo T-D265C30.2115CLd4 T-D265C30.2115CLinPBS "11HET T-0265C30.2115CLdo 10-1410-1310-1210-1110-1010-9 3.080e-011 120 110 100 90 80 70 60 50 40 30 20 10 0 ] % [ Viability 10-7 10-8 -04TD2650-302060 9.937e-011 Concentration[M] T-D2650-30.206004 T-D265C30.2060inPBS T-D265C30.2060do 10-1410-1310-1210-1110-1010-9 5.665e-011 1207 110 100 90 80 70 60 404 30 20 10 PBSinafterincubationcellsSKBRCytotoxicity-3on ] % [ Viability ?????????????????????????????????????????????? 10-8 T-0265C30.169904 5.980e-011 Concentration(M) T-D265C30.169904 T-D265C30.1699inPBS T-D2650-30.1699do 10-1410-1310-1210-1110-2010-9 2.344e-011 FIGURE12 0 120 110 100 90 80 70 60 50 40 30 20 10 ] % [ Viability Patent Application Publication Oct.
Load more

Recommended publications
  • Relationship Between the Conformation of the Cyclopeptides Isolated from the Fungus Amanita Phalloides (Vaill. Ex Fr.) Secr. and Its Toxicity
    Molecules 2000, 5 489 Relationship Between the Conformation of the Cyclopeptides Isolated from the Fungus Amanita Phalloides (Vaill. Ex Fr.) Secr. and Its Toxicity M.E. Battista, A.A. Vitale and A.B. Pomilio PROPLAME-CONICET, Departamento de Química Orgánica, Facultad de Ciencias Exactas y Natu- rales, Universidad de Buenos Aires, Pabellón 2, Ciudad Universitaria, 1428 Buenos Aires, Argentina E-mail: [email protected] Abstract: The electronic structures and conformational studies of the cyclopeptides, O- methyl-α-amanitin, phalloidin and antamanide, were obtained from molecular parameters on the basis of semiempiric and ab initio methods. Introduction During this century Amanita phalloides - the most toxic fungus known up to now - has been studied from different points of view. This basidiomycete biosynthesizes mono- and bicyclic peptides com- posed of rare amino acids. In order to determine the structure/activity relationships chemical modifica- tions were carried out and the properties of these compounds were evaluated. These results were con- firmed by studying the conformations of three selected compounds representative of the major groups of the macroconstituents of this fungus. Experimental Hyperchem package (HyperCube, version 5.2) was used for semiempirical studies, the molecular geometry being optimized by STO-631G. Net charges were calculated with HyperCube PM3 and the Polack-Ribiere algoritm. GAUSSIAN 98 was used for ab initio studies. Results and Discussion We were interested in obtaining information on the conformations that the cyclic peptides may adopt and about the potential energy maps in order to locate the regions related to the binding to pro- tein molecules, such as F-actin and RNA-polymerase.
    [Show full text]
  • Meeting Key Synthetic Challenges in Amanitin Synthesis with a New Cytotoxic Analog: 50-Hydroxy- Cite This: Chem
    Chemical Science View Article Online EDGE ARTICLE View Journal | View Issue Meeting key synthetic challenges in amanitin synthesis with a new cytotoxic analog: 50-hydroxy- Cite this: Chem. Sci., 2020, 11, 11927 0 † All publication charges for this article 6 -deoxy-amanitin have been paid for by the Royal Society of Chemistry Alla Pryyma, Kaveh Matinkhoo, Antonio A. W. L. Wong and David M. Perrin * Appreciating the need to access synthetic analogs of amanitin, here we report the synthesis of 50-hydroxy- Received 29th July 2020 60-deoxy-amanitin, a novel, rationally-designed bioactive analog and constitutional isomer of a-amanitin, Accepted 2nd October 2020 that is anticipated to be used as a payload for antibody drug conjugates. In completing this synthesis, we DOI: 10.1039/d0sc04150e meet the challenge of diastereoselective sulfoxidation by presenting two high-yielding and rsc.li/chemical-science diastereoselective sulfoxidation approaches to afford the more toxic (R)-sulfoxide. drug-tolerant cell subpopulations.7 Examples include ADCs for Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Introduction targeting human epidermal growth factor receptor 2 and pros- 8 9 a-Amanitin, the deadliest of the amatoxins produced by the tate specic membrane antigen. With but a few exceptions, death-cap mushroom Amanita phalloides, is a potent, orally nearly all bioconjugates to a cytotoxic amanitin have emerged 1 a available inhibitor of RNA polymerase II (pol II) (Ki 10 nM), from naturally-sourced -amanitin. To date, conjugation that has been validated as a payload for targeted cancer handles used for a-amanitin-based bioconjugates include the d- 2a therapy.2 First described in 1907 3 and isolated in 1941,4 a- hydroxyl of (2S,3R,4R)-4,5-dihydroxyisoleucine (DHIle), the 10 0 amanitin is a compact bicyclic octapeptide that has been asparagine side chain, and the 6 -hydroxyl of the tryptathio- 11 indispensable for probing RNA pol II-catalysed transcription in nine staple.
    [Show full text]
  • WSC 2000-01 Conference 1
    The Armed Forces Institute of Pathology Department of Veterinary Pathology WEDNESDAY SLIDE CONFERENCE 2002-2003 CONFERENCE 17 12 February 2003 Conference Moderator: LTC Gary Zaucha, DVM Diplomate, ACVP, ABT, and ACVPM Chief, Department of Comparative Pathology Walter Reed Army Institute of Research Silver Spring, MD 20910 CASE I – 1614-1 (AFIP 2850109) Signalment: 5-month-old outbred female Swiss-Webster mouse History: Sentinel mouse in a laboratory colony housed on dirty bedding from other mouse cages, part of an infectious disease surveillance program. Euthanized due to lethargy and unthriftiness. Gross Pathology: Stomach distended approximately three times by gas, fluid, and partially digested food. Kidneys shrunken, pale, and pitted. Multifocal hemorrhagic necrosis and thrombosis of the ovaries bilaterally. Laboratory Results: Negative for all murine infectious pathogens tested in the colony surveillance program by serology, respiratory and intestinal cultures, fecal examination, anal tape, and skin scrapings. Contributor’s Morphologic Diagnosis: Kidney: Chronic nephropathy characterized by membranous glomerulopathy, lymphoplasmacytic adventitial vasculitis and perivasculitis, tubular degeneration, ectasia, and regeneration with protein, hemoglobin, cellular, waxy, and granular casts, and lymphoplasmacytic and histiocytic interstitial nephritis, severe. Contributor’s Comment: This case is consistent with the previously reported syndrome of gastric dilatation and chronic nephropathy in mice exposed to dirty bedding [1]. Although the mean age of affected mice in the published report was 10 months, similar lesions are sometimes found in animals as young as 3 or 4 months of age. The kidney disease appears immune-mediated and is presumably the result of chronic high antigen exposure, although there may be more than one inciting process.
    [Show full text]
  • Toxic Fungi of Western North America
    Toxic Fungi of Western North America by Thomas J. Duffy, MD Published by MykoWeb (www.mykoweb.com) March, 2008 (Web) August, 2008 (PDF) 2 Toxic Fungi of Western North America Copyright © 2008 by Thomas J. Duffy & Michael G. Wood Toxic Fungi of Western North America 3 Contents Introductory Material ........................................................................................... 7 Dedication ............................................................................................................... 7 Preface .................................................................................................................... 7 Acknowledgements ................................................................................................. 7 An Introduction to Mushrooms & Mushroom Poisoning .............................. 9 Introduction and collection of specimens .............................................................. 9 General overview of mushroom poisonings ......................................................... 10 Ecology and general anatomy of fungi ................................................................ 11 Description and habitat of Amanita phalloides and Amanita ocreata .............. 14 History of Amanita ocreata and Amanita phalloides in the West ..................... 18 The classical history of Amanita phalloides and related species ....................... 20 Mushroom poisoning case registry ...................................................................... 21 “Look-Alike” mushrooms .....................................................................................
    [Show full text]
  • Determination of Mushroom Toxin Alpha-Amanitin in Serum by Liquid Chromatography-Mass Spectrometry After Solid-Phase Extraction
    Original article UDC: 615.918:582.28 doi:10.5633/amm.2015.0102 DETERMINATION OF MUSHROOM TOXIN ALPHA-AMANITIN IN SERUM BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY AFTER SOLID-PHASE EXTRACTION Maja Vujović1,2, Ivana Ilić3, Vesna Kilibarda4 University of Niš, Faculty of Medicine, Department of Pharmacy, Serbia1 Institute of Forensic Medicine, Niš, Serbia2 University of Niš, Faculty of Medicine, Serbia3 Military Medical Academy Belgrade, National Poison Control Centre, Serbia4 Alpha-amanitin is a cyclic peptide which belongs to a large group of mushroom toxins known as amatoxins. Being responsible for the majority of fatal mushroom poisonings, they require rapid detection and excretion from the body fluids. In accordance with these requirements, a simple and an accurate method was developed for successful identification and quantification of alpha-amanitin in serum with electrospray liquid chromatography–mass spectrometry (LC-ESI-MS) after collision-induced dissociation. The method conforms to the established International Conference on Harmonization Q2A/Q2B 1996 guidelines on the validation of analytical methods. Linearity, precision, extraction recovery and stability test on blank serum spiked with alpha-amanitin and stored in different conditions met the acceptance criteria. The obtained calibration curve was linear over the concentration range 5-100 ng/mL with a lower limit of quantification (LOQ) of 5 ng/mL and limit of detection (LOD) of 2.5 ng/mL. The mean intra- and inter-day precision and accuracy were 6.05% and less than ±15% of nominal values, respectively. The neutral solid phase extraction with copolymer hydrophilic–lipophilic balance cartridges was found optimal for sample preparation with the mean recovery of 91.94%.
    [Show full text]
  • Sequencing Abstracts Msa Annual Meeting Berkeley, California 7-11 August 2016
    M S A 2 0 1 6 SEQUENCING ABSTRACTS MSA ANNUAL MEETING BERKELEY, CALIFORNIA 7-11 AUGUST 2016 MSA Special Addresses Presidential Address Kerry O’Donnell MSA President 2015–2016 Who do you love? Karling Lecture Arturo Casadevall Johns Hopkins Bloomberg School of Public Health Thoughts on virulence, melanin and the rise of mammals Workshops Nomenclature UNITE Student Workshop on Professional Development Abstracts for Symposia, Contributed formats for downloading and using locally or in a Talks, and Poster Sessions arranged by range of applications (e.g. QIIME, Mothur, SCATA). 4. Analysis tools - UNITE provides variety of analysis last name of primary author. Presenting tools including, for example, massBLASTer for author in *bold. blasting hundreds of sequences in one batch, ITSx for detecting and extracting ITS1 and ITS2 regions of ITS 1. UNITE - Unified system for the DNA based sequences from environmental communities, or fungal species linked to the classification ATOSH for assigning your unknown sequences to *Abarenkov, Kessy (1), Kõljalg, Urmas (1,2), SHs. 5. Custom search functions and unique views to Nilsson, R. Henrik (3), Taylor, Andy F. S. (4), fungal barcode sequences - these include extended Larsson, Karl-Hnerik (5), UNITE Community (6) search filters (e.g. source, locality, habitat, traits) for 1.Natural History Museum, University of Tartu, sequences and SHs, interactive maps and graphs, and Vanemuise 46, Tartu 51014; 2.Institute of Ecology views to the largest unidentified sequence clusters and Earth Sciences, University of Tartu, Lai 40, Tartu formed by sequences from multiple independent 51005, Estonia; 3.Department of Biological and ecological studies, and for which no metadata Environmental Sciences, University of Gothenburg, currently exists.
    [Show full text]
  • Biosynthesis of Cyclic Peptide Natural Products in Mushrooms
    BIOSYNTHESIS OF CYCLIC PEPTIDE NATURAL PRODUCTS IN MUSHROOMS By Robert Michael Sgambelluri A DISSERTATION Submitted to Michigan State University in partial fulfillment of the requirements for the degree of Biochemistry & Molecular Biology – Doctor of Philosophy 2017 ABSTRACT BIOSYNTHESIS OF CYCLIC PEPTIDE NATURAL PRODUCTS IN MUSHROOMS By Robert Michael Sgambelluri Cyclic peptide compounds possess properties that make them attractive candidates in the development of new drugs and therapeutics. Mushrooms in the genera Amanita and Galerina produce cyclic peptides using a biosynthetic pathway that is combinatorial by nature, and involves an unidentified, core set of tailoring enzymes that synthesize cyclic peptides from precursor peptides encoded in the genome. The products of this pathway are collectively referred to as cycloamanides, and include amatoxins, phallotoxins, peptides with immunosuppressant activities, and many other uncharacterized compounds. This work aims to describe cycloamanide biosynthesis and its capacity for cyclic peptide production, and to harness the pathway as a means to design and synthesize bioactive peptides and novel compounds. The genomes of Amanita bisporigera and A. phalloides were sequenced and genes encoding cycloamanides were identified. Based on the number of genes identified and their sequences, the two species are shown to have a combined capacity to synthesize at least 51 unique cycloamanides. Using these genomic data to predict the structures of uncharacterized cycloamanides, two new cyclic peptides, CylE and CylF, were identified in A. phalloides by mass spectrometry. Two species of Lepiota mushrooms, previously not known to produce cycloamanides, were also analyzed and shown to contain amatoxins, the toxic cycloamanides responsible for fatal mushroom poisonings. The mushroom Galerina marginata, which also produces amatoxins, was used as a model orgasnism for studying cycloamanide biosynthesis due to its culturability.
    [Show full text]
  • A Report on Mushrooms Poisonings in 2018 at the Apulian Regional Poison Center
    Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia Open Access Macedonian Journal of Medical Sciences. 2020 Sep 03; 8(E):616-622. https://doi.org/10.3889/oamjms.2020.4208 eISSN: 1857-9655 Category: E - Public Health Section: Public Health Disease Control A Report on Mushrooms Poisonings in 2018 at the Apulian Regional Poison Center Leonardo Pennisi1, Anna Lepore1, Roberto Gagliano-Candela2*, Luigi Santacroce3, Ioannis Alexandros Charitos1 1Department of Emergency/Urgent, National Poison Center, Azienda Ospedaliero Universitaria Ospedali Riuniti, Foggia, Italy; 2Department of Interdisciplinary Medicine, Forensic Medicine, University of Bari, Bari, Italy; 3Ionian Department, Microbiology and Virology Lab, University of Bari, Bari, Italy Abstract Edited by: Sasho Stoleski BACKGROUND: The “Ospedali Riuniti’s Poison Center” (Foggia, Italy) provides a 24 h telephone consultation in Citation: Pennisi L, Lepore A, Gagliano-Candela R, Santacroce L, Charitos IA. A Report on Mushrooms clinical toxicology to the general public and health-care professionals, including drug information and assessment of Poisonings in 2018 at the Apulian Regional Poison Center. the effects of commercial and industrial chemical substances, toxins but also plants and mushrooms. It participates Open Access Maced J Med Sci. 2020 Sep 03; 8(E):616-622. in diagnosis and treatment of the exposure to toxins and toxicants, also throughout its ambulatory activity. https://doi.org/10.3889/oamjms.2020.4208 Keywords: Poisoning; Intoxication; Epidemiology; Poison center; Mushroom poisoning METHODS: To report data on the epidemiology of mushroom poisoning in people contacting our Poison Center we *Correspondence: Roberto Gagliano-Candela, made computerized queries and descriptive analyses of the medical records database of the mushroom poisoning Department of Interdisciplinary Medicine, Forensic in the poison center of Foggia from January 2018 to December 2018.
    [Show full text]
  • Expansion and Diversification of the MSDIN Family of Cyclic Peptide Genes in the Poisonous Agarics Amanita Phalloides and A
    Pulman et al. BMC Genomics (2016) 17:1038 DOI 10.1186/s12864-016-3378-7 RESEARCHARTICLE Open Access Expansion and diversification of the MSDIN family of cyclic peptide genes in the poisonous agarics Amanita phalloides and A. bisporigera Jane A. Pulman1,2, Kevin L. Childs1,2, R. Michael Sgambelluri3,4 and Jonathan D. Walton1,4* Abstract Background: The cyclic peptide toxins of Amanita mushrooms, such as α-amanitin and phalloidin, are encoded by the “MSDIN” gene family and ribosomally biosynthesized. Based on partial genome sequence and PCR analysis, some members of the MSDIN family were previously identified in Amanita bisporigera, and several other members are known from other species of Amanita. However, the complete complement in any one species, and hence the genetic capacity for these fungi to make cyclic peptides, remains unknown. Results: Draft genome sequences of two cyclic peptide-producing mushrooms, the “Death Cap” A. phalloides and the “Destroying Angel” A. bisporigera, were obtained. Each species has ~30 MSDIN genes, most of which are predicted to encode unknown cyclic peptides. Some MSDIN genes were duplicated in one or the other species, but only three were common to both species. A gene encoding cycloamanide B, a previously described nontoxic cyclic heptapeptide, was also present in A. phalloides, but genes for antamanide and cycloamanides A, C, and D were not. In A. bisporigera, RNA expression was observed for 20 of the MSDIN family members. Based on their predicted sequences, novel cyclic peptides were searched for by LC/MS/MS in extracts of A. phalloides. The presence of two cyclic peptides, named cycloamanides E and F with structures cyclo(SFFFPVP) and cyclo(IVGILGLP), was thereby demonstrated.
    [Show full text]
  • Conference 1 C O N F E R E N C E 16 29 January 2020 18 August, 2021 Dr
    Joint Pathology CeJointnter Pathology Center Veterinary PatholVeterinaryogy Service Pathologys Services WEDNESDAY SLIDE CONFERENCE 2021-2022 WEDNESDAY SLIDE CONFER ENCE 2019-2020 Conference 1 C o n f e r e n c e 16 29 January 2020 18 August, 2021 Dr. Ingeborg Langohr, DVM, PhD, DACVP Professor Department of Pathobiological Sciences Louisiana S tate University School of Veterinary Medicine Baton RouJointge, L APathology Center Silver Spring, Maryland CASE I: CASE S1809996 1: 1 ((4152313JPC 4135077-00) ). Microscoptan/purple.ic Descr ipThetio n:medullary The inte rstitparenchymaium was within thedisrupted section isby diff dozensusel yof infilt brightra tedred btoy dull purple SignalmeSignalment:nt: A 3-mont h-old, male, mixed- moderate linesto lar thatge radiatednumbers from of pre thedomi levelna ofntl they renal crest breed pig 6(-Susmonth scrofa-old )male (intact) mastiff (Canis mononuclethroughar cell thes a lonmedulla.g with edema. There familiaris). is abunda nt type II pneumocyte hyperplasia History: This pig had no previous signs of lining alveolar septae and many of the illness, andHistory: was found dead. The patient was referred to a veterinary medicalalveola r spaces have central areas of Gross Patholteachingogy : hospitalApprox imfollowingately 70% an o facute, 1-dayne- crotic macrophages admixed with other the lungs,history primar ofily lethargy in the c andrani ainappetencel regions o fthat quicklymononucle ar cells and fewer neutrophils. the lobes, progressedwere patch toy obtundation. dark red, and Bloodwork firm performedOc casionally there is free nuclear basophilic comparedat to thethe rDVMmore norevealedrmal ar etooas ofhigh lun tog. read ALT, elevated ALP (805 U/L), hypoalbuminemia (2.7 Laboratorg/dL)y re suandlts: hypoglycemia Porcine reprodu (23 cmg/dL).tive PT and and respiraaPTTtory weresyndrome both prolonged (PRRS) PCat >100R wa secs and >300 positive frsec,om sprespectively.lenic tissue, Protein and P RandRS IHCbilirubin were was strongdetectedly immunore on a urineactive dipstick.
    [Show full text]
  • The Effect of a High-Resolution Accurate Mass Spectrometer On
    GÜFBED/GUSTIJ (2020) 10 (4): 878-886 Gümüşhane Üniversitesi Fen Bilimleri Enstitüsü Dergisi DOI: 10.17714/gumusfenbil.680816 Araştırma Makalesi / Research Article The Effect of A High-Resolution Accurate Mass Spectrometer On Simultaneous Multiple Mushroom Toxin Detection Yüksek Çözünürlüklü Kütle Spektrometrenin Eşzamanlı Çoklu Mantar Toksin Tayinleri Üzerindeki Etkisi Yasemin NUMANOĞLU ÇEVİK*1,2,a 1MoH, Turkish Public Health General Directorate, Microbiology Reference Laboratory, Adnan Saygun Street 55, 06100 Sıhhıye, Ankara, TURKEY 2Separation Science Group, Department of Organic and Macromolecular Chemistry, Ghent University, Krijgslaan 281 S4-Bis, 9000 Gent, Belgium • Geliş tarihi / Received: 29.01.2020 • Düzeltilerek geliş tarihi / Received in revised form: 17.06.2020 • Kabul tarihi / Accepted: 02.07.2020 Abstract Amatoxins are deadly wild mushroom toxins that cause severe poisoning in humans, from diarrhea to organ dysfunction. Mortality can be as high as 80% if no specific treatment is applied. In this study, separation and determination methods were developed for the simultaneous determination of 7 toxins belonging to Amanita phalloides. After extraction and purification of Amanita phalloides (death cap) wild mushrooms, toxins were detected using HPLC- ESI MS and exact mass with time of flight MS (TOF-MS) in positive ionization mode. In addition, it was observed that the toxins of α- and β-amanitine could be differentiated from each other thanks to HR-MS detection in case of their close retention (Rt) in LC. The presence of two toxins at the same retention point in the chromatogram was detected by differentiating the molecular ion mass (920.3514 DA) of the α-amanitine with the HR-MS (920.3696 DA).
    [Show full text]
  • Determination of Mushroom Toxin Alpha-Amanitin in Serum by Liquid Chromatography-Mass Spectrometry After Solid-Phase Extraction
    Original article UDC: 615.918:582.28 doi:10.5633/amm.2015.0102 DETERMINATION OF MUSHROOM TOXIN ALPHA-AMANITIN IN SERUM BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY AFTER SOLID-PHASE EXTRACTION Maja Vujović1,2, Ivana Ilić3, Vesna Kilibarda4 University of Niš, Faculty of Medicine, Department of Pharmacy, Serbia1 Institute of Forensic Medicine, Niš, Serbia2 University of Niš, Faculty of Medicine, Serbia3 Military Medical Academy Belgrade, National Poison Control Centre, Serbia4 Alpha-amanitin is a cyclic peptide which belongs to a large group of mushroom toxins known as amatoxins. Being responsible for the majority of fatal mushroom poisonings, they require rapid detection and excretion from the body fluids. In accordance with these requirements, a simple and an accurate method was developed for successful identification and quantification of alpha-amanitin in serum with electrospray liquid chromatography–mass spectrometry (LC-ESI-MS) after collision-induced dissociation. The method conforms to the established International Conference on Harmonization Q2A/Q2B 1996 guidelines on the validation of analytical methods. Linearity, precision, extraction recovery and stability test on blank serum spiked with alpha-amanitin and stored in different conditions met the acceptance criteria. The obtained calibration curve was linear over the concentration range 5-100 ng/mL with a lower limit of quantification (LOQ) of 5 ng/mL and limit of detection (LOD) of 2.5 ng/mL. The mean intra- and inter-day precision and accuracy were 6.05% and less than ±15% of nominal values, respectively. The neutral solid phase extraction with copolymer hydrophilic–lipophilic balance cartridges was found optimal for sample preparation with the mean recovery of 91.94%.
    [Show full text]